- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00240019
Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
October 16, 2006 updated by: Stanford University
Maximizing the Benefit of RAS Blockade in Diabetic Nephropathy
The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy.
The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which is a sign of disease, more than an angiotensin converting enzyme inhibitor alone.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Santa Clara, California, United States, 95051
- Kaiser Permanente of Northern California, Santa Clara and San Jose
-
Stanford, California, United States, 94305
- Stanford University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
proteinuria greater than 1 gram/day serum creatinine < 2.6 for men, < 2.0 for women
Exclusion Criteria:
blood pressure which cannot be controlled without a diuretic renal diseases other than diabetic nephropathy other disease which would alter renal function during 6 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The amount of protein in the urine after 8 weeks of treatment.
|
Secondary Outcome Measures
Outcome Measure |
---|
The estimated glomerular filtration rate after 8 weeks of treatment.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Timothy W Meyer, MD, Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2003
Study Completion
April 1, 2006
Study Registration Dates
First Submitted
October 13, 2005
First Submitted That Met QC Criteria
October 13, 2005
First Posted (Estimate)
October 17, 2005
Study Record Updates
Last Update Posted (Estimate)
October 17, 2006
Last Update Submitted That Met QC Criteria
October 16, 2006
Last Verified
June 1, 2006
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Endocrine System Diseases
- Diabetes Complications
- Diabetes Mellitus
- Kidney Diseases
- Diabetic Nephropathies
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Sodium Potassium Chloride Symporter Inhibitors
- Furosemide
Other Study ID Numbers
- R01-063011
- R01DK063011 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Nephropathy
-
Assiut UniversityUnknownDiabetic Nephropathy Type 2
-
Zheng GuoNot yet recruitingDiabetic Nephropathy Type 2
-
The Third Xiangya Hospital of Central South UniversityCompletedType 2 Diabetic NephropathyChina
-
Centro Universitario de Ciencias de la Salud, MexicoUnknownDiabetic Nephropathy Type 2Mexico
-
Second Affiliated Hospital, School of Medicine,...Second Affiliated Hospital of Wenzhou Medical University; Lishui Country People...RecruitingDiabetic Nephropathy Type 2 | BiomarkerChina
-
University of Sao Paulo General HospitalCompleted
-
Assiut UniversityNot yet recruitingType 2 DM é Diabetic Nephropathy
-
Chinese PLA General HospitalCompletedInsulin Pump Therapy in Treating Diabetic Nephropathy
-
PfizerTerminatedType 2 Diabetic NephropathyUnited States
-
Chang Gung Memorial HospitalUnknown
Clinical Trials on Addition of furosemide 20 mg oral bid to baseline regimen
-
BiocodexRecruitingChronic Renal InsufficiencyBulgaria
-
Iyad Naeem Muhammad, PhDCompletedHelicobacter Pylori Infection | Helicobacter Pylori Infection, Susceptibility toPakistan
-
Assistance Publique - Hôpitaux de ParisRecruitingPrimary Sclerosing Cholangitis | CholestasisFrance
-
Rambam Health Care CampusCompletedChronic Heart Failure | Congestive Heart Failure | Diuretics Drug ReactionsIsrael
-
Médecins Sans Frontières, FranceHarvard Medical School (HMS and HSDM); Institute of Tropical Medicine, Belgium and other collaboratorsActive, not recruitingBacterial Infections | Gram-Positive Bacterial Infections | Tuberculosis | Tuberculosis, Multidrug-Resistant | Pulmonary Tuberculoses | Mycobacterial InfectionsVietnam, Pakistan, India, Kazakhstan, Lesotho, Peru
-
University of Texas Southwestern Medical CenterNational Center for Research Resources (NCRR)CompletedPulmonary Arterial HypertensionUnited States
-
King's College Hospital NHS TrustKing's College London; Fight for Sight (Funder)RecruitingEye Diseases | Macular Degeneration, Wet | Sub-Macular HemorrhageUnited Kingdom
-
Federico II UniversityRecruitingBurning Mouth SyndromeItaly